SureTrader
Home > Boards > US Listed > Biotechs >

Opko Health Inc (OPK)

OPK RSS Feed
Add OPK Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 1/18/2018 2:26:21 PM - Followers: 162 - Board type: Free - Posts Today: 0

Opko Health Initiates Phase 3 Trial of Bevasiranib for the Treatment of AMD Wednesday July 11, 8:00 am ET -Trial Designed to Compare Efficacy of Bevasiranib Administered Every 8 Weeks or 12 Weeks with Lucentis(R) Administered Every 4 Weeks- -Represents First-Ever Phase 3 Pivotal Trial of an RNAi Therapeutic- MIAMI, July 11 /PRNewswire-FirstCall/ -- Opko Health Inc. (Amex: OPK - News) today announced the initiation of the Phase 3 COBALT (Combining Bevasiranib And Lucentis Therapy) clinical trial of bevasiranib for the treatment of wet age-related macular degeneration (wet AMD.) The multi-national COBALT study is currently open and enrolling patients. The trial will include more than 330 wet AMD patients and will assess whether bevasiranib administered every 8 or 12 weeks is safe and has equivalent efficacy in preventing vision loss as Genentech's Lucentis® administered every four weeks. ADVERTISEMENT Bevasiranib is a first-in-class small interfering RNA (siRNA) drug designed to silence the genes that produce vascular endothelial growth factor (VEGF), believed to be largely responsible for the vision loss of wet AMD. Bevasiranib is the first therapy based on the Nobel Prize-winning RNA interference (RNAi) technology to advance to Phase 3 clinical trials. "This first-ever Phase 3 trial of an agent based on RNAi technology is an important milestone in this new field. We are proud of the ability demonstrated by our clinical group to have successfully moved this innovative compound through development rapidly and cost effectively," said Philip Frost, M.D., Chairman and CEO of Opko Health. "Currently patients with wet AMD undergo intravitreal injections every four weeks to achieve the vision- preserving benefits of Lucentis, so the potential ability of bevasiranib to achieve similar results while requiring less frequent injections would be an important benefit for these patients who often have limited mobility." "Bevasiranib's demonstrated safety profile, its ability to inhibit the growth of the retinal lesions associated with wet AMD and its potential for prolonged duration are a promising foundation for this pivotal trial," said Lawrence Singerman M.D., founder and Executive Secretary of the Macula Society, Clinical Professor of Ophthalmology at Case University and a Principal Investigator for the Phase 3 study. "Bevasiranib's potential to serve as a long-term maintenance therapy for wet AMD could provide important benefits to patients, and I look forward to helping to assess its utility in this groundbreaking study." "We are very pleased at the enthusiastic reception the COBALT trial has received from retinal centers around the globe," said Denis O'Shaughnessy, Ph.D., Senior Vice President of Clinical Development at Opko. "Retinal physicians are keenly aware of the burden that frequent drug injections places on elderly patients and their families, and they are eager to help test an innovative new approach that has the potential to significantly reduce that burden while preserving patients' vision." About Wet AMD Wet age-related macular degeneration is the leading cause of irreversible vision loss in the developed world and its incidence is growing rapidly. Advanced age is the main risk factor for wet AMD, and it is expected to become an increasingly common condition as the population grows older. An estimated 1.65 million Americans have wet AMD today and an estimated 11 million people worldwide will have AMD by 2013. Until recently, treatments for wet AMD were of limited efficacy. In the search for more effective treatments, researchers targeted VEGF, shown to be a key cause of the excess growth and leakiness of ocular blood vessels that result in loss of vision in these patients. Current VEGF antagonists, such as Lucentis, slow this vision loss, but require injections into the eye every four weeks, a particular issue for elderly patients who often have limited mobility. Opko Health, Inc. Announces Early Termination of Hart-Scott-Rodino Waiting Period for Proposed Purchase of Shares by Dr. Phillip Frost Thursday July 12, 8:00 am ET MIAMI July 12 /PRNewswire-FirstCall/ -- Opko Health Inc. (Amex: OPK - News) today announced that that the U.S. Department of Justice has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in connection with the potential acquisition of additional shares of Opko Health common stock by Dr. Phillip Frost, CEO and Chairman of Opko. Dr. Frost has requested clearance to purchase additional shares of Opko Health common stock, which this action by the Justice Department now makes feasible.
SureTrader
OPK
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
OPK News: OPKO’S GeneDx Announces Research Collaboration with Radboud University Medical Center 01/12/2018 08:00:00 AM
OPK News: Current Report Filing (8-k) 12/28/2017 04:33:37 PM
OPK News: OPKO Health Enrolls First Patient in Phase 2B Study of OPK88004 to Treat Benign Prostatic Hypertrophy 11/27/2017 11:02:41 AM
OPK News: Xenetic Biosciences Reports 2017 Third Quarter Financial Results and Provides Corporate Update 11/15/2017 07:05:00 AM
OPK News: Current Report Filing (8-k) 11/13/2017 04:03:06 PM
PostSubject
#5870   Very possible. game7alcs 01/18/18 02:26:21 PM
#5869   Game perhaps Dr. Frost has stopped buying due tredenwater2 01/18/18 09:33:35 AM
#5868   Alnylam stock more than tripled last year — terry hallinan 01/18/18 07:14:09 AM
#5867   I my opinion , Dr. Frost stop buying Sky10 01/17/18 04:00:25 PM
#5866   One thing seems certain. Something is up or game7alcs 01/17/18 12:56:15 PM
#5865   I bought 4000 shares a few years back Stify 01/17/18 11:21:40 AM
#5864   I don't see a reverse split but I game7alcs 01/17/18 11:12:46 AM
#5863   Seems more like dropko, as of last 2 years... Stify 01/17/18 11:08:42 AM
#5862   Yea I thought we had a winner here. game7alcs 01/16/18 08:35:46 PM
#5861   Yes I am so tired of this honestly Juice555 01/16/18 07:34:07 PM
#5860   If they are really in the midst of game7alcs 01/16/18 07:32:46 PM
#5859   I believe the BOD should also step down.. now invest 01/16/18 03:17:10 PM
#5858   News? Wtf going on? Sone 01/16/18 02:40:17 PM
#5857   So frustrating. Really don't understand what they are thinking Juice555 01/16/18 02:10:10 PM
#5856   Should be in the 3s soon. game7alcs 01/16/18 02:05:55 PM
#5855   Why? Because the DOW hit 26000 and OPKO game7alcs 01/16/18 11:07:13 AM
#5854   This is getting more disgusting every day..... The now invest 01/16/18 11:03:23 AM
#5853   Any one here familiar with the "building" of tredenwater2 01/14/18 11:21:21 PM
#5852   I'm sure this is a good thing but game7alcs 01/12/18 09:47:13 AM
#5851   Sky, You just had to pull rank on me terry hallinan 01/10/18 01:48:19 PM
#5850   Terry , Sky10 01/10/18 01:32:21 PM
#5849   For Sky10 and anybody else interested terry hallinan 01/10/18 08:38:25 AM
#5848   And when photons replace electrons, how will your terry hallinan 01/09/18 07:03:41 PM
#5847   Like many other members of this board , Sky10 01/09/18 04:12:35 PM
#5846   Yes Something is for sure going on with all Juice555 01/08/18 05:40:57 PM
#5845   "I wonder why OPKO hasn't announced that they tredenwater2 01/08/18 05:29:35 PM
#5844   FBN with Maria having a segment on the game7alcs 01/08/18 08:07:52 AM
#5843   I would think that the whole management team homeboy 01/07/18 11:31:46 AM
#5842   No doubt So it going up from 1.14 ( Juice555 01/03/18 10:51:29 PM
#5841   Yea me too. This was my last big game7alcs 01/03/18 10:46:59 PM
#5840   Yes Just need one more miracle ( rabbit) from Juice555 01/03/18 10:44:20 PM
#5839   I don't blame you. I'm not sure why game7alcs 01/03/18 10:42:30 PM
#5838   I hope Dr frost buddies covered their short Juice555 01/03/18 10:36:38 PM
#5837   Happy New Year Juice game7alcs 12/29/17 11:43:28 AM
#5836   Thanks Let's see what happens in the next few Juice555 12/29/17 11:40:51 AM
#5835   I really don't know. It looks like a game7alcs 12/29/17 11:34:23 AM
#5834   ??? What does it mean? Bad or good for Juice555 12/29/17 11:11:34 AM
#5833   Item 2.03. Creation of a Direct Financial Obligation game7alcs 12/29/17 10:24:40 AM
#5832   Concerning the “weed” stock, did you buy “high” DegenerateGambler 12/27/17 08:10:46 PM
#5831   I sold my 2000 shares today. Purchased weed Picks77 12/27/17 07:49:44 PM
#5830   Game, Your contempt for diversification matches that of a terry hallinan 12/27/17 03:15:11 PM
#5829   Exactly Dr frost can use his own funds to Juice555 12/27/17 03:05:26 PM
#5828   That would be nice but from a purely game7alcs 12/27/17 02:43:36 PM
#5827   OPKO Health Reports 4.7% Stake in Eloxx Pharmaceuticals terry hallinan 12/27/17 02:40:30 PM
#5826   Agreed game7alcs 12/27/17 01:52:46 PM
#5825   That's nice But where is our stock going??? Juice555 12/27/17 01:37:16 PM
#5824   OPKO Health Reports 4.7% Stake in Eloxx Pharmaceuticals game7alcs 12/27/17 10:36:18 AM
#5823   This whole silent period seems to be because terry hallinan 12/24/17 12:08:43 PM
#5822   lol gotcha.. Congrats!! game7alcs 12/22/17 06:25:32 PM
#5821   Actually... this time... got another and sold half now invest 12/22/17 01:34:09 PM
PostSubject